Maryam Hafizi - Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.- Cancer Research Center , Shahid Beheshti University of Medical Sciences, Tehran, Iran
Somayeh Kalanaky - Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Saideh Fakharzadeh - Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Mohammad Vasei - Department of Pathology Tehran University of Medical Sciences,Tehran, Iran

In spite of all the efforts and researches on anticancer therapeutics, an absolute treatment is still a myth. It is evident that current drugs are not able to efficiently target the underlying pathogenesis on higher levels of cellular signalling and by affecting different pathways. So this multifactorial natured medusa has the upper hand. For the first time, we synthesized BCc1 nano complex based on the novel nanochelating technology and evaluated its anticancer effects, in vivo and in vitro. The results revealed an intelligent, targeted and multi-functional antineoplastic behavior of this nano complex considering that it showed low normal cell cytotoxicity and high malignant growth suppression in cellular and animal models by a different performance from other medications. Thus, BCc1 can be considered as a profitable candidate for further complementary evaluations to introduce a new generation of anticancer medications with completely superior function